Does oxidation dominate for liraglutide held at 2–8 °C?

Conditions: oxidation · liraglutide · 2–8 °C.

This is one of those things that everyone repeats and nobody derives.

This matters practically, not just academically, because it changes what I would do next.

Is the standard explanation correct, and if so, what is the evidence for it?

At 2–8 °C the question is which route is fastest, not whether oxidation happens — and the routes do not share an activation energy, so their ranking changes with temperature. 2–8 °C is the condition the rule of thumb is anchored to, so it is the baseline rather than a multiplier: everything else in this thread is quoted relative to it. That multiplier is an average over every route at once, which is exactly why it cannot tell you which one wins. Met and Trp take up oxygen sixteen daltons at a time, and the oxidised species is more polar, so on a reversed-phase column it elutes ahead of the parent rather than behind it. So the way to answer it for your vial is to pick the method that sees oxidation specifically and run it against a control held cold, rather than to infer a mechanism from a purity number that averages all of them.

Start with the sequence, because which pathways are available depends on which residues are present.

Hydrolysis cleaves the backbone, most readily at aspartate-proline and aspartate-glycine sequences, and is acid-catalysed. In a dry solid it barely proceeds at all.

Aggregation is physical: peptides unfold at air-liquid interfaces and associate. Shaking maximises that interface, which is why swirling and shaking produce visibly different outcomes on the same vial.

Metal-catalysed oxidation of methionine is documented across peptide and protein formulations and is why chelators appear in some formulations.

Swirl, never shake. Aggregation is a handling problem more than a time problem.

edited 4 Sept 2025 by RP_C18 — added the placebo-arm figures

Answer first: the degradation pathways worth knowing are hydrolysis, deamidation, oxidation, aggregation and adsorption, and each has a different trigger and a different mitigation.

Oxidation targets methionine, cysteine and tryptophan, adding sixteen daltons per oxygen. It is catalysed by trace metals and promoted by dissolved oxygen and by light.

Stated carefully, freeze-thaw cycling drives aggregation through concentration at the ice interface and pH shifts as buffer components crystallise out at different rates. Each cycle costs something.

Adsorption losses at low concentrations are quantified in formulation studies and are the reason carrier proteins are used in dilute preparations.

A mass spectrum names the pathway. Plus one, plus sixteen, minus eighteen.

Answering this needs the physical state, since a dry powder is protected from most of these and a solution is protected from none.

Light exposure matters for tryptophan-containing sequences and for anything with a chromophore. Amber vials and a closed box are free mitigations.

The underlying point is that adsorption onto glass and plastic is significant at low concentrations — micrograms per millilitre — and negligible at milligrams per millilitre. It is the usual explanation for an apparent loss in a dilute preparation.

Nothing here is medical advice, and research-use compounds are not approved for human use.

Cold, dry, dark, still. Those four words cover most of the mitigation.

Concretely, asparagine and glutamine are the deamidation risk, and methionine is the oxidation risk.

A mass spectrum resolves most of this: minus eighteen is dehydration or succinimide, plus one is deamidation, plus sixteen is oxidation, and an unchanged mass with a shifted retention time is an isomer.

Deamidation via the succinimide intermediate is well characterised, with sequence-dependent rates highest for asparagine-glycine motifs.

At dilute concentrations, suspect adsorption before you suspect chemistry.

More usefully, aggregation is a physical process and is the one most often caused by handling rather than by time.

Deamidation converts asparagine or glutamine to the corresponding acid via a succinimide intermediate, adding one dalton. It is base-catalysed, accelerates above neutral pH and is the dominant aqueous pathway for many peptides.

Aggregation at air-liquid interfaces is established from surface-tension and particle-count studies and is the basis for anti-agitation handling guidance.

Apparent loss in a dilute preparation is usually adsorption rather than degradation and is worth ruling out first.

Sequence decides which pathways are even available. Check the residues.